Supernus Pharmaceuticals, Inc.

DB:S49 Stock Report

Market Cap: €1.9b

Supernus Pharmaceuticals Valuation

Is S49 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of S49 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: S49 (€34.2) is trading below our estimate of fair value (€157.83)

Significantly Below Fair Value: S49 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for S49?

Key metric: As S49 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for S49. This is calculated by dividing S49's market cap by their current earnings.
What is S49's PE Ratio?
PE Ratio32.8x
EarningsUS$59.71m
Market CapUS$1.96b

Price to Earnings Ratio vs Peers

How does S49's PE Ratio compare to its peers?

The above table shows the PE ratio for S49 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.5x
DMP Dermapharm Holding
22.6x17.0%€2.0b
PSG PharmaSGP Holding
15.1x13.6%€283.0m
2FJ0 Pierrel
29.9xn/a€92.8m
MRK Merck KGaA
22.3x11.1%€60.1b
S49 Supernus Pharmaceuticals
32.8x36.2%€2.0b

Price-To-Earnings vs Peers: S49 is expensive based on its Price-To-Earnings Ratio (32.8x) compared to the peer average (22.5x).

Price to Earnings Ratio vs Industry

How does S49's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
S49 32.8xIndustry Avg. 19.3xNo. of Companies11PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: S49 is expensive based on its Price-To-Earnings Ratio (32.8x) compared to the European Pharmaceuticals industry average (19.3x).

Price to Earnings Ratio vs Fair Ratio

What is S49's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

S49 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio32.8x
Fair PE Ratio22.5x

Price-To-Earnings vs Fair Ratio: S49 is expensive based on its Price-To-Earnings Ratio (32.8x) compared to the estimated Fair Price-To-Earnings Ratio (22.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst S49 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€34.20
€37.16
+8.7%
6.6%€40.71€34.08n/a4
Dec ’25€35.00
€35.93
+2.6%
6.6%€39.36€32.95n/a4
Nov ’25€31.00
€36.13
+16.5%
6.6%€39.58€33.14n/a4
Oct ’25€27.80
€35.60
+28.1%
6.6%€39.00€32.65n/a4
Sep ’25€31.40
€37.08
+18.1%
4.5%€39.37€34.79n/a4
Aug ’25€27.40
€37.69
+37.6%
4.5%€40.02€35.37n/a4
Jul ’25€24.60
€37.69
+53.2%
4.5%€40.02€35.37n/a4
Jun ’25€24.40
€37.69
+54.5%
4.5%€40.02€35.37n/a4
May ’25€28.40
€37.37
+31.6%
4.5%€39.68€35.07n/a4
Apr ’25€31.00
€37.37
+20.6%
4.5%€39.68€35.07n/a4
Mar ’25€27.40
€37.37
+36.4%
4.5%€39.68€35.07n/a4
Feb ’25€25.40
€38.45
+51.4%
5.2%€40.33€35.64n/a4
Jan ’25€26.40
€38.45
+45.6%
5.2%€40.33€35.64n/a4
Dec ’24€24.80
€38.45
+55.0%
5.2%€40.33€35.64€35.004
Nov ’24€22.40
€38.57
+72.2%
4.7%€40.70€35.96€31.004
Oct ’24€26.40
€38.23
+44.8%
6.1%€40.72€34.38€27.804
Sep ’24€29.20
€38.23
+30.9%
6.1%€40.72€34.38€31.404
Aug ’24€27.80
€38.23
+37.5%
6.1%€40.72€34.38€27.404
Jul ’24€27.40
€39.16
+42.9%
7.2%€41.89€34.61€24.604
Jun ’24€30.80
€39.16
+27.1%
7.2%€41.89€34.61€24.404
May ’24€33.40
€40.10
+20.0%
6.7%€42.21€35.64€28.404
Apr ’24€33.20
€40.10
+20.8%
6.7%€42.21€35.64€31.004
Mar ’24€35.40
€40.10
+13.3%
6.7%€42.21€35.64€27.404
Feb ’24€37.40
€39.80
+6.4%
7.7%€43.25€34.97€25.404
Jan ’24€33.40
€37.59
+12.5%
11.3%€42.03€30.82€26.404
Dec ’23€35.00
€38.62
+10.4%
10.8%€42.95€32.96€24.803

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 20:29
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Supernus Pharmaceuticals, Inc. is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarBerenberg
David BuckB. Riley Securities, Inc.
John TannerCantor Fitzgerald & Co.